The BD&L Summit for Life Sciences

Unlock the potential of a deal through optimized business development activities and transactional excellence to drive a company's competitive position in today's marketplace

San Francisco, CA, United States

The growing emergence of biotech companies and specialized knowledge base has lead to a shift in strategic focus for life science companies. Even though R&D spend is on the rise, companies still look to external targets as a means of supplementing pipelines and bolstering their product portfolios. The need to expand the reach of R&D programs has driven major new investments in co-development, licensing, acquisitions and strategic alliances, as companies look to gain access to new sources of innovation.

With so many factors affecting the potential value of a transaction, it is essential for life science organizations to effectively assess the risks associated with a deal, explore innovative models and deal structures for working with strategic partners, collaborate with cross-functional partners to realize business synergies, and develop processes for the efficient and optimal negotiation and closing of a transaction.

The BD&L Summit for Life Sciences will provide attendees with valuable insights and actionable strategies from cross-functional business development teams in successfully managing alliances, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and will feature leadership representation from biotechs, mid-sized and large pharmaceutical, medical device and diagnostics companies.

Who Should Attend:

This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
  • Business Development
  • Mergers and Acquisitions
  • Licensing
  • Strategic Alliance/Alliance Management
  • Intellectual Property and Patent Counsel
  • Search and Evaluation
  • Due Diligence
  • External Innovation
  • Transactions
  • Portfolio Management
  • Scientific Assessment
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Regulatory Affairs
  • Research and Development
  • Clinical Medicine
  • Clinical Operations
  • Lifecycle Management

This conference is also of interest to:
  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Partners


  • Mike Myers, Senior Director, Lilly Research Labs - Due Diligence, ELI LILLY
  • Catherine Baillis, Vice President, Head of Business Development Operations, Business Development and Licensing, SANOFI
  • Martin Picard, Ph.D., Head, Search, Evaluation and Due Diligence, Biopharma R&D/External Innovation, MERCK KGAA
  • Marc Schwabish, Ph.D., Senior Vice President, Business Development and U.S. Operations, FUSION PHARMACEUTICALS


Hyatt Fisherman's Wharf
555 North Point Street
San Francisco, CA 94133
Event details
Organizer : ExL Events
Venue : Hyatt Fisherman's Wharf, San Francisco, CA, United States
Event type : Conference
Reference : ASDE-19088